1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 2:Age, race, and frontal lobe tumor involvement of patient groups
All (n = 20) Female (n = 11) Male (n = 9) High Movers (n = 9) Low Movers (n = 11) Age (mean) 45.3 ± 16.4 40.7 ± 17.7 50.9 ± 14.3 38.1 ± 15.3 51.2 ± 15.5 Age range (yr) 21–75 21–75 28–67 21–66 29–75 Race (White/Black/Hispanic/Asian) (No.) 15/2/2/1 8/2/1/0 7/0/1/1 6/1/1/1 9/1/1/0 No. of patients with tumor with frontal lobe involvement 11 (55%) 7 (64%) 4 (44%) 8 (89%) 3 (27%)